New Vitalis Pharmacy made sterile compounded drugs under insanitary conditions that risked contamination.
What happened
FDA inspected New Vitalis Pharmacy from August 23 to August 27, 2021, and noted serious deficiencies in producing drug products intended or expected to be sterile. Investigators observed vermin next to the production area, dirty and hard-to-clean surfaces including black residue in an ISO 7 cleanroom and around HEPA filters, blocked first air, unsealed HEPA filters, poor glove and component disinfection, improper gowning, and inadequate cleaning of utensils used with hazardous drugs. After the inspection, the firm recalled all Testosterone Cypionate/Testosterone Propionate 180mg/mL, 20mg/mL within expiry made on or before September 7, 2021, and stopped all sterile compounding on September 7, 2021.
What FDA found
Vermin were observed in an area immediately next to the production area.
FDCA section 501(a)(2)(A)Production areas were difficult to clean or had porous, particle-generating, or visibly dirty surfaces, including debris on the floor, peeling tape with black residue in the ISO 7 cleanroom, and black residue around HEPA filters.
FDCA section 501(a)(2)(A)An operator blocked first air by placing gloved hands directly over open sterile containers.
FDCA section 501(a)(2)(A)HEPA filters were not sealed around each perimeter to the support frame.
FDCA section 501(a)(2)(A)Personnel failed to disinfect gloves and components and improperly donned gowning apparel in ways that could cause contamination.
FDCA section 501(a)(2)(A)The firm handled hazardous drug products without adequate cleaning of utensils to prevent cross-contamination.
FDCA section 501(a)(2)(A)
What FDA wants
Within 15 working days, notify FDA in writing of the specific steps taken to address the violations, or state that you do not intend to resume sterile production. If you intend to resume, include an explanation of steps to prevent recurrence, related documentation, and notify FDA 15 days before resuming.
Who should pay attention
- patients and clinicians using compounded sterile drugs
- compounding pharmacies and sterile outsourcing facilities
- buyers or distributors of compounded testosterone products
This is a summary. Read the original letter on fda.gov.